Search

GlaxoSmithKline PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

1,389.5 -0.22

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1378.5

Max

1397

Pagrindiniai rodikliai

By Trading Economics

Pajamos

559M

501M

Pardavimai

105M

8.1B

P/E

Sektoriaus vid.

21.557

57.333

Pelnas, tenkantis vienai akcijai

23.2

Dividendų pajamingumas

4.79

Pelno marža

6.172

Darbuotojai

68,629

EBITDA

-52M

1.1B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+13.6% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.79%

2.63%

Kitas uždarbis

2025-04-30

Kitas dividendų mokėjimo data

2025-07-10

Kita Ex Dividend data

2025-05-15

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5.9B

54B

Ankstesnė atidarymo kaina

1389.72

Ankstesnė uždarymo kaina

1389.5

GlaxoSmithKline PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-09 09:39; UTC

Pagrindinės rinkos jėgos

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025-02-05 11:32; UTC

Uždarbis

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

2025-02-05 08:56; UTC

Uždarbis

Correction to GSK Article

2025-02-05 08:24; UTC

Uždarbis

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

2025-02-05 07:43; UTC

Uždarbis

GSK Expects Further Profit Growth After Beating Market Views

2025-04-23 21:48; UTC

Svarbiausios naujienos

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

2025-04-23 20:47; UTC

Svarbiausios naujienos

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

2025-04-23 20:40; UTC

Svarbiausios naujienos

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

2025-04-15 09:55; UTC

Rinkos pokalbiai

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2025-04-09 07:23; UTC

Rinkos pokalbiai

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

2025-04-03 08:41; UTC

Rinkos pokalbiai

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

2025-04-03 08:36; UTC

Rinkos pokalbiai

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

2025-04-03 07:51; UTC

Rinkos pokalbiai

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2025-04-02 09:27; UTC

Karštos akcijos

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

2025-03-26 22:29; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

2025-03-26 19:19; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

2025-03-26 17:39; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

2025-03-19 14:50; UTC

Svarbiausios naujienos

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

2025-03-17 09:00; UTC

Svarbiausios naujienos

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

2025-02-24 07:05; UTC

Įsigijimai, susijungimai, perėmimai

GSK Completes Acquisition of IDRx

2025-02-14 11:38; UTC

Svarbiausios naujienos
Uždarbis

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

2025-02-14 11:30; UTC

Svarbiausios naujienos
Uždarbis

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

2025-02-05 15:33; UTC

Rinkos pokalbiai
Uždarbis

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

2025-02-05 08:38; UTC

Rinkos pokalbiai
Uždarbis

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

2025-02-05 07:05; UTC

Uždarbis

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

2025-02-05 07:04; UTC

Uždarbis

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

2025-02-05 07:03; UTC

Uždarbis

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

2025-02-05 07:03; UTC

Uždarbis

GSK PLC Raises Mid-Term View

2025-02-05 07:03; UTC

Uždarbis

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

2025-02-05 07:02; UTC

Uždarbis

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

GlaxoSmithKline PLC Prognozė

Kainos tikslas

By TipRanks

13.6% į viršų

12 mėnesių prognozė

Vidutinis 1,583.64 GBX  13.6%

Aukščiausias 2,290 GBX

Žemiausias 1,350 GBX

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines GlaxoSmithKline PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

11 ratings

1

Pirkti

8

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.